Rituximab Plus Avacopan Increases Remission Rates in ANCA-Associated Vasculitis

Rituximab Plus Avacopan Increases Remission Rates in ANCA-Associated Vasculitis

Anisha Dua, MD, MPH Credit: American College of Rheumatology Convergence Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with rituximab (RTX) showed a significant increase in remission sustained at …

Read more